Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase. by Breccia, Massimo et al.
Mediterr J Hematol Infect Dis 2011, 3; Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Original Articles
Low  Incidence  Rate  of  Opportunistic 
Treatment in Chronic Myeloid Leukemia Patients 
Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo 
Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli and
Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Correspondence to: Massimo Breccia, MD. 
Benevento 6, 00161 Rome, Italy. Tel. +39 06 857951, Fax +39 06 44241984. e
Competing interests: The authors have declared th
Published: May 16, 2011
Received: April 18, 2011
Accepted: May 9, 2011
Mediterr J Hematol  Infect Dis 2011, 3: e20110
This article is available from: http://www.mjhid.org/article/view/
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License 
(http://creativecommons.org/licenses/by/2.0
provided the original work is properly cited.
   
Abstract:  Background: Imatinib  has  become  first  line  therapy  in  chronic  myeloid  leukemia
patients. Little is known about the infective consequences during the treatment with this drug in 
large series of chronic phase patients. 
Material and methods: From January 2001 to September 2006 we treated with imatinib 250 patients 
in first line (early CP) or after interferon failure (late CP), out of clinical trials and recorded all the 
bacterial and viral infections occurred.
Results: We recorded a similar incidence of bacterial and viral infections both in first line and late 
CP patients  (respectively, 16%  and 13%) during 3.5 years of follow
features  predisposing  to  infections  revealed  differences  only  in  late  CP  patients,  with  elevated 
percentage of high Sokal risk patients and a more longer median time from diagnosis to st
imatinib.
Conclusions: Opportunistic  infections  and  reactivation  of  Herpes  Zoster  are  observed  during 
imatinib therapy at very low incidence.
Introduction: Targeted inhibition of BCR
imatinib mesylate has become the standard therapy for 
patients with chronic myeloid leukaemia (CML) where 
it  induces  a  complete  cytogenetic  response  in  more 
than  80%  of  newly diagnosed patients.
year  follow-up  of  IRIS  study  showed  an  overall 
survival (OS) of 85% and event-free survival (EFS) of 
81%.
2 Several years after the introduction of imatinib 
in  clinical practice no significant major  incidence of 
infections was reported. However, different evidences 
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Imatinib  has  become  first  line  therapy  in  chronic  myeloid  leukemia
patients. Little is known about the infective consequences during the treatment with this drug in 
large series of chronic phase patients. 
From January 2001 to September 2006 we treated with imatinib 250 patients 
CP) or after interferon failure (late CP), out of clinical trials and recorded all the 
bacterial and viral infections occurred.
We recorded a similar incidence of bacterial and viral infections both in first line and late 
y, 16%  and 13%) during 3.5 years of follow-up. Analysis of presenting 
features  predisposing  to  infections  revealed  differences  only  in  late  CP  patients,  with  elevated 
percentage of high Sokal risk patients and a more longer median time from diagnosis to st
Opportunistic  infections  and  reactivation  of  Herpes  Zoster  are  observed  during 
imatinib therapy at very low incidence.
Targeted inhibition of BCR-ABL with 
imatinib mesylate has become the standard therapy for 
patients with chronic myeloid leukaemia (CML) where 
it  induces  a  complete  cytogenetic  response  in  more 
than  80%  of  newly diagnosed patients.
1 A  recent  8-
p  of  IRIS  study  showed  an  overall 
free survival (EFS) of 
Several years after the introduction of imatinib 
in  clinical practice no significant major  incidence of 
infections was reported. However, different evidences 
that imatinib  can  impair  several  cellular  functions 
involved in the immune response have been observed, 
in  particular  in  cell-mediated  immunity.
here on the incidence of infectious episodes observed 
during imatinib treatment in our large series of 
and late chronic phase CML patients. 
Patients and Methods: All consecutive patients with 
Ph+ CML in chronic phase out of clinical trials who 
started  with imatinib therapy during  the  period from
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Imatinib  has  become  first  line  therapy  in  chronic  myeloid  leukemia
patients. Little is known about the infective consequences during the treatment with this drug in 
From January 2001 to September 2006 we treated with imatinib 250 patients 
CP) or after interferon failure (late CP), out of clinical trials and recorded all the 
We recorded a similar incidence of bacterial and viral infections both in first line and late 
up. Analysis of presenting 
features  predisposing  to  infections  revealed  differences  only  in  late  CP  patients,  with  elevated 
percentage of high Sokal risk patients and a more longer median time from diagnosis to start of 
Opportunistic  infections  and  reactivation  of  Herpes  Zoster  are  observed  during 
imatinib  can  impair  several  cellular  functions 
involved in the immune response have been observed, 
mediated  immunity.
3-5 We  refer 
here on the incidence of infectious episodes observed 
during imatinib treatment in our large series of early 
and late chronic phase CML patients. 
All consecutive patients with 
Ph+ CML in chronic phase out of clinical trials who 
therapy during  the  period fromMediterr J Hematol Infect Dis 2011, 3; Open Journal System
Table 1. Characteristics of patients and of infective episodes.
Characteristics Early chronic 
phase
Late chronic phase Total population
Number of patients 100 150 250
Age years, median (range) 54 (22-79) 56 (21-82) 55 (21-82)
Sex M/F, number of patients 66/34 82/68 148/102
Follow up years, median (range) 3.5 (2-7) 4 (2.2-9) 4.2 (2-9)
Time from start of imatinib therapy and first infectious 
episode, weeks (range)
13 (9-26) 20(10-28) 15(9-28)
Neutropenia (ANC< 500/cmm) during imatinib therapy, 
number of patients (%)
14 (14%) 12 (8%) 26 (10%)
Infections, number of patients (%)
   Febrile neutropenia of unknown origin  
   Pneumonia
   Pericarditis
   Urinary tract infection
   Orchitis
   Herpes zoster






















*One patient developed two episodes of pneumonia. In the second episode pulmonary tuberculosis was diagnosed.
January 2001 to September 2006 were included in the 
study. The observation was interrupted on December 
2009  and  patients lost  to  follow-up were  considered 
until last visit.  Overall 250 patients were considered: 
150 patients had received prior therapy with Interferon 
(IFN) for a median of 24 months (range 5-68) and were 
considered in late chronic phase (CP) and, whereas 100 
patients received imatinib soon after diagnosis (early 
CP).  No  differences  were  observed  regarding  Sokal 
risk: in early CP patients at baseline, 45% were low 
risk, 24% intermediate and 3% were high risk. In late 
CP  group,  Sokal  risk  at  the  time  of  imatinib  start 
revealed 43% of patients as low risk, 50% intermediate 
and  6.6%  as  high  risk.  Before  starting  imatinib,  all 
patients  had  baseline  evaluation  including  physical 
examination,  complete  blood  cell  count,  renal  and 
hepatic  function  tests,  serum  protein  electrophoresis, 
serum levels of IgG, IgA and IgM, bone marrow (BM) 
aspirate with cytogenetic and molecular analyses, chest 
X  ray and  cardiac  evaluation.   Physical examination 
and complete blood cell count were performed weekly 
for the first month, then monthly. During treatment, all 
side effects possibly related to drug and all infective 
episodes,  were  evaluated  and  collected  by  medical 
staff.  Only  clinically  and  microbiologically 
documented infections were included. Febrile episodes 
of unknown origin in non-neutropenic patients (ANC > 
500/cmm), upper respiratory tract syndromes possibly 
related  to  a  viral  infection  and  localized  Herpes 
simplex were not considered in the analysis. 
Results:  Overall,  36  clinically  or  microbiologically 
documented  infections  that  required  antibacterial  or 
antiviral therapy and discontinuation of imatinib were 
recorded  in  35  patients  (incidence  14%).  The 
characteristics  of  the  infective  episodes  are 
summarized in table 1.
In  the  series  of  100  CP  patients  who  received 
imatinib as first line therapy, with a median follow-up 
of 3.5 years, we recorded 17 infectious episodes in 16 
patients  (incidence  16%).  They  accounted  for  0.02 
infectious  episodes  per  1000  patient  days.  All  the 
infective  episodes  occurred  at  a  median  time  of  13 
weeks  (range  9-26)  from  the  onset  of  imatinib 
treatment.  No  episode  was  associated  to  deep 
neutropenia  (absolute  neutrophyl  count  <  500/cmm). 
Median  gammaglobulin  dosage was  0.82  g/dl (range 
0.7-2),  with  only  1  patient  presented  with  a  slightly 
inferior  dosage.  Herpes  zoster  and  pneumonia 
represented  the  two  more  frequently  observed 
infections  occurring  in  7%  and  4%  of  patients, 
respectively.  In  all  patients  who  developed  Herpes 
zoster  a  reduction  of  lymphocyte  count  (median 
lymphocytes count 0.6 x 10
9/l, range 0.2-1.1, compared 
to 0.9 x 10
9/l of patients who did not developed viral 
infections) was evidenced at the time of viral infection 
(median  time  of  development  11  weeks),  in  the 
absence of induced leukopenia and serum Ig level (0.9 
g/dl).  One  out  of  the  4  subjects  who  developed 
pneumonia presented two additional episodes of fever 
with radiological  evidence  of  pulmonary  infiltrate 
diagnosed  as  tuberculosis.  This  second  infection 
occurred  soon  after  underlying  hematologic  disease 
progression to accelerated phase. 
In the series of 150 patients treated with imatinib
after resistance/intolerance to interferon, observed for a Mediterr J Hematol Infect Dis 2011, 3; Open Journal System
Table 2. Comparison of patients who developed infections and patients who did not
median follow-up of 4 years, we recorded 19 infective 
episodes (13%). They accounted for 0.003 infectious 
episodes  per  1000  patient  days.  Three  episodes  of 
pneumonia  and  2  urinary  tract  infections  occurred 
during  neutropenia  phase.  Median  gammaglobulin 
dosage  was  0.93  g/dl  (range  0.6-2.1),  with  only  2 
patients  presented  with  a  slightly  inferior  dosage. 
Fourteen late CP  patients developed a  Herpes zoster 
infection during treatment with imatinib (median time 
of development 14 weeks): these patients, as observed 
in  the  cohort  of  early  CP  patients,  had  a  significant 
reduction  of  lymphocyte  count  at  the  time  of  viral 
infection (median lymphocytes count 0.8 x 10
9/l, range 
0.2-1.2, compared to 1.1 x 10
9/l of patients who did not 
developed  viral  infections),  in  the  absence  of 
leukopenia and serum Ig level (0.8 g/dl). The infective 
episodes  developed  at  a  median  time  of  20  weeks 
(range 10-28) from the onset of imatinib treatment and 
all occurred during neutropenia induced by the drug, 
differently from what  observed in  early CP  patients. 
No infection-related death occurred and all infections 
resolved in both groups of patients. Presenting features 
of patients who developed infections and of those who 
did  not were  compared  (Table  2).  In  the  group  of 
subjects  in  early  CP  there  were  no  statistically 
significant differences between patients who developed 
infections and patients who did not. In patients in late 
CP a longer interval of time between diagnosis and the 
start  of  imatinib  (17  vs  9  months,  p=0.02)  and  a 
prevalence of high Sokal risk (p=0.03) was observed in 
patients who developed an infectious complication. 
Discussion: Clinical and laboratory findings seem to 
show that imatinib can impair several cellular functions 
involved  in  the  immune  response.  Two  different 
studies referred on a reduction of the immunoglobulin 
levels  during  imatinib  treatment  for  CML  and  for 
gastrointestinal stromal tumors (GIST).
6,7 In the report 
of Steegmann et al
6 only a slight decrease of Ig levels 
in imatinib treated patients who had became resistant 
or intolerant to interferon-alpha was documented: the 
authors cannot rule out the possibility of an influence 
by the prior therapy and suggested an impairment of B-
lymphocytes  or  a  mediated  effect  through  the 
inhibition of ABL kinase. Santachiara et al
7 reported 
on  87  late  CP  patients  treated  with  imatinib  who 
presented a reduction of Ig levels; these patients were 
treated  with  imatinib  after  IFN  for  CML  or  were 
affected  by  GIST.  The  authors  did  exclude  that  this 
effect  had  to  be  ascribed  to  interferon  therapy  and 
suggested that it had to be considered the consequence 
of the imatinib treatment. CML patients in CP are at 
low  infectious  risk  compared  to  patients  in  more 
advanced disease phases, however the epidemiological 
impact of infectious complications in the imatinib era 
is unknown as infections have not been enclosed in the 
safety analysis of large imatinib studies.
2,8 Few reports 
on  non-viral  infections  have  been  published  during 
imatinib  therapy  and  anecdotic  cases  of  pulmonary 
nocardiosis, pulmonary tuberculosis, fungal pneumonia 
and listeria meningitis have been reported.
9-12 In two of 
these observations, the infections were concomitant to 
lymphopenia  and  monocytopenia.  On  the  contrary, 
viral  infections,  particularly  those  caused  by  herpes 
viruses,  seem  to  have  a  higher  epidemiological 
impact.
13-15 Mattiuzzi et al
13 reported on a frequency of 
2% of VZV reactivation in CML patients treated with 
imatinib:  baseline  features  of  these  subjects  did  not 
differ significantly from those of patients who did not 
develop  VZV  infection,  except  for  the  time  from 
diagnosis to imatinib treatment and the number of prior 
therapies. Few case reports reported on the occurrence 
of other viral infections during imatinib therapy.
14-16 In 
particular, the case of a fatal HHV8 infection in a CML 
patient in complete molecular remission after imatinib 
was  recently  reported.
15 In  our  experience,  bacterial 
infection had a very low epidemiological and clinical 
impact but VZV disease occurred more frequently than 
previously  reported.
13 Contrary  to  the  study  by 
Mattiuzzi  et  al,
13 all  patients  enclosed  in  our  series 
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from diagnosis to 
start of imatinib 
(months)
1.5 2 0.233 17 9 0.02Mediterr J Hematol Infect Dis 2011, 3; Open Journal System
were  out  of  clinical  trials,  probably  with  less 
favourable clinical characteristics. In fact, all patients 
who developed the viral infection were aged over 50 
years and had comorbidities, such as diabetes and/or 
cardiac  disease, conditions which contraindicated the 
inclusion in clinical trials. We did not find differences 
in  the  VZV  incidence  between  early and  late  CP 
patients  (7%  vs  9%).  In  any  case,  VZV  infections 
accounted for only 0.04 infectious episodes per 1000 
patient  days  in  the  overall  population,  therefore 
prophylaxis  of  VZV  infection  may  not  be 
recommended  in  this  setting,  considering  also  the 
limited extent of the disease and the prompt response 
to therapy. As to bacterial infections in late CP group, 
we  found  that  a  longer  interval  of  time  between 
diagnosis and the start of imatinib and a prevalence of 
high  Sokal  risk  were  prognostic  adverse  events 
compared to early CP group: a possible explanation is 
that  previous  treatment  and  high  Sokal  risk  may 
influence  the  rate  of  infections  due  to  the  possible 
scarce reserve of Ph negative cells. Infectious episodes 
appeared concentrated in the first period of treatment: 
this is in line with data from trials,
2 in which toxicity 
was observed in  the first year of treatment and new 
events did not occur lately, again probably related to 
the initial massive reduction of leukemic burden.
Conclusions: We  observed  that  opportunistic 
infections are an unusual complication also in a “real 
life” population of CP - CML patients under imatinib 
therapy. No life threatening and easy to treat Herpes 
zoster  reactivations  represents  the  most  frequently 
observed infectious complications.
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